Yifan Pharmaceutical Co., Ltd. (SHE:002019)
China flag China · Delayed Price · Currency is CNY
9.24
+0.05 (0.54%)
Oct 28, 2026, 3:04 PM CST

Yifan Pharmaceutical Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Operating Revenue
4,9055,1065,1404,0443,8194,379
Other Revenue
26.6126.6120.2923.6117.5130.45
4,9325,1335,1604,0683,8374,409
Revenue Growth
-5.60%-0.52%26.84%6.03%-12.98%-18.36%
Cost of Revenue
2,6872,7572,7452,1391,9832,594
Gross Profit
2,2452,3762,4141,9291,8531,815
Selling, General & Admin
1,4371,5761,6291,5031,4351,297
Research & Development
313.32291.37291.97312.38190.2196.64
Other Operating Expenses
118.0244.2943.4632.3727.0537.24
Operating Expenses
1,8741,9352,0261,9081,6821,552
Operating Income
370.88441.78388.5220.93171.35262.68
Interest Expense
-49.65-53.04-69.1-75.55-85.85-74.59
Interest & Investment Income
11.8412.068.1213.1321.3925.3
Currency Exchange Gain (Loss)
-1.75-1.75-2.9414.550.19-17.77
Other Non Operating Income (Expenses)
-38.1-9.65-0.29-14.84-12.38-8.03
EBT Excluding Unusual Items
293.22389.4324.3-41.83144.69187.59
Impairment of Goodwill
------11.9
Gain (Loss) on Sale of Investments
-30.1-27.45-14.16-15.06-17.63-4.49
Gain (Loss) on Sale of Assets
1.0412.730.152.57-0.5614.83
Asset Writedown
-30.37-30.37-73.69-872.42-102.13-26.34
Other Unusual Items
89.0479.43122.0657.71132.3751.1
Pretax Income
322.83423.7388.66-869.03156.74210.79
Income Tax Expense
49.8350.2565.0416.6229.65-31.42
Earnings From Continuing Operations
273373.45323.62-885.65127.09242.21
Minority Interest in Earnings
38.2128.5762.35334.5864.1336.18
Net Income
311.21402.02385.97-551.07191.22278.4
Net Income to Common
311.21402.02385.97-551.07191.22278.4
Net Income Growth
-23.61%4.16%---31.31%-71.25%
Shares Outstanding (Basic)
1,2181,2181,2061,2251,1951,210
Shares Outstanding (Diluted)
1,2181,2181,2061,2251,2751,210
Shares Change
1.32%1.00%-1.51%-3.94%5.32%-1.26%
EPS (Basic)
0.260.330.32-0.450.160.23
EPS (Diluted)
0.260.330.32-0.450.150.23
EPS Growth
-24.60%3.13%---34.78%-70.89%

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Free Cash Flow
-27.34-100.8712.57-155.5-70.21-270.51
Free Cash Flow Per Share
-0.02-0.080.01-0.13-0.06-0.22
Dividend Per Share
0.1000.1000.200---
Dividend Growth
0%-50.00%300.00%---
Gross Margin
45.52%46.29%46.79%47.42%48.30%41.16%
Operating Margin
7.52%8.61%7.53%0.52%4.47%5.96%
Profit Margin
6.31%7.83%7.48%-13.55%4.98%6.31%
Free Cash Flow Margin
-0.55%-1.97%0.24%-3.82%-1.83%-6.13%
EBITDA
708.44772.16709.34273.5379.13453.82
EBITDA Margin
14.37%15.04%13.75%6.72%9.88%10.29%
D&A For EBITDA
337.56330.39320.83252.57207.78191.14
EBIT
370.88441.78388.5220.93171.35262.68
EBIT Margin
7.52%8.61%7.53%0.51%4.47%5.96%
Effective Tax Rate
15.43%11.86%16.73%-18.92%-
Revenue as Reported
4,9325,1335,1604,0683,8374,409